Loreto Carmona Ortells-rekin lankidetzan egindako argitalpenak (12)

2024

  1. SLESIS-R: an improved score for prediction of serious infection in patients with systemic lupus erythematosus based on the RELESSER prospective cohort

    Lupus Science and Medicine, Vol. 11, Núm. 1

2021

  1. Influence of prognosis factors on the prescription of targeted treatments in rheumatoid arthritis: A Delphi survey

    Joint Bone Spine, Vol. 88, Núm. 4

2020

  1. Practical Aspects of Biological Throught Levels and Antidrug Antibodies in Rheumatoid Arthritis and Spondyloarthritis

    Reumatologia Clinica, Vol. 16, Núm. 5, pp. 378-385

2019

  1. Discordance between doctor and patient assessments and non-adherence to subcutaneous biological drugs

    Rheumatology International, Vol. 39, Núm. 6, pp. 1077-1082

2018

  1. Correction to: The beliefs of rheumatoid arthritis patients in their subcutaneous biological drug: strengths and areas of concern (Rheumatology International, (2018), 38, 9, (1735-1740), 10.1007/s00296-018-4097-y)

    Rheumatology International

  2. Serum drug levels of biologic agents in the management of rheumatoid arthritis and spondyloarthritis: a systematic review

    Rheumatology International, Vol. 38, Núm. 6, pp. 975-983

  3. The beliefs of rheumatoid arthritis patients in their subcutaneous biological drug: strengths and areas of concern

    Rheumatology International, Vol. 38, Núm. 9, pp. 1735-1740

  4. Use of prognostic factors of rheumatoid arthritis in clinical practice and perception of their predictive capacity before and after exposure to evidence

    Rheumatology International, Vol. 38, Núm. 12, pp. 2289-2296

2017

  1. Disease Activity As a Major Determinant of Quality of Life and Physical Function in Patients With Early Axial Spondyloarthritis

    Arthritis Care and Research, Vol. 69, Núm. 1, pp. 150-155

  2. Identification of patients at risk of non-adherence to oral antirheumatic drugs in rheumatoid arthritis using the Compliance Questionnaire in Rheumatology: an ARCO sub-study

    Rheumatology International, Vol. 37, Núm. 7, pp. 1195-1202

  3. Non-adherence to subcutaneous biological medication in patients with rheumatoid arthritis: A multicentre, non-interventional study

    Clinical and Experimental Rheumatology, Vol. 35, Núm. 3, pp. 423-430

  4. The Challenge of Assessing Adherence to Subcutaneous Biological Drugs in Immune-Mediated Inflammatory Diseases. Letter to the Editor Regarding Michetti P, Weinman J, Mrowietz U, et al. Adv Ther (2017);34:91–108. doi:10.1007/s12325-016-0441-3

    Advances in Therapy